Explore

Trendline Trendline
Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Agreement

Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Agreement

Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Agreement
Trendline Trendline
Innate Pharma to Engage with Investors at Jefferies Global Healthcare Conference in New York

Innate Pharma to Engage with Investors at Jefferies Global Healthcare Conference in New York

Innate Pharma to Engage with Investors at Jefferies Global Healthcare Conference in New York
Trendline Trendline
MSD's Sac-TMT Shows Promise in Phase 3 Endometrial Cancer Trial

MSD's Sac-TMT Shows Promise in Phase 3 Endometrial Cancer Trial

MSD's Sac-TMT Shows Promise in Phase 3 Endometrial Cancer Trial
Trendline Trendline
Myosin Therapeutics Begins Phase 1/2 Trial of MT-125 for Glioblastoma Treatment

Myosin Therapeutics Begins Phase 1/2 Trial of MT-125 for Glioblastoma Treatment

Myosin Therapeutics Begins Phase 1/2 Trial of MT-125 for Glioblastoma Treatment
Trendline Trendline
Aspera Biomedicines Launches ADAR1p150 Crystallization Experiment to ISS for Cancer Research

Aspera Biomedicines Launches ADAR1p150 Crystallization Experiment to ISS for Cancer Research

Aspera Biomedicines Launches ADAR1p150 Crystallization Experiment to ISS for Cancer Research
Trendline Trendline
Onco-Innovations Advances Key Materials for ONC010 Development

Onco-Innovations Advances Key Materials for ONC010 Development

Onco-Innovations Advances Key Materials for ONC010 Development
Trendline Trendline
Innate Pharma to Engage Investors at Jefferies Global Healthcare Conference

Innate Pharma to Engage Investors at Jefferies Global Healthcare Conference

Innate Pharma to Engage Investors at Jefferies Global Healthcare Conference
Trendline Trendline
Revolution Medicines' Pancreatic Cancer Drug Poised for FDA Approval, Analysts Predict Major Impact

Revolution Medicines' Pancreatic Cancer Drug Poised for FDA Approval, Analysts Predict Major Impact

Revolution Medicines' Pancreatic Cancer Drug Poised for FDA Approval, Analysts Predict Major Impact
Trendline Trendline
Lantern Pharma's HARMONIC Trial Receives FDA Support for Protocol Amendments in NSCLC Treatment

Lantern Pharma's HARMONIC Trial Receives FDA Support for Protocol Amendments in NSCLC Treatment

Lantern Pharma's HARMONIC Trial Receives FDA Support for Protocol Amendments in NSCLC Treatment
Trendline Trendline
Lantern Pharma's LP-300 Trial for Never-Smokers with NSCLC Advances with FDA Support

Lantern Pharma's LP-300 Trial for Never-Smokers with NSCLC Advances with FDA Support

Lantern Pharma's LP-300 Trial for Never-Smokers with NSCLC Advances with FDA Support
Trendline Trendline
WuXi Biologics Hosts CRDMO Day in Japan to Boost Biopharma Innovation

WuXi Biologics Hosts CRDMO Day in Japan to Boost Biopharma Innovation

WuXi Biologics Hosts CRDMO Day in Japan to Boost Biopharma Innovation
Trendline Trendline
Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Deal

Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Deal

Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Deal